Ascendis Pharma A/S at JPMorgan Healthcare Conference Transcript
Good morning, everyone. My name is Jess Fye. I'm one of the biotech analysts at JPMorgan. And we're delighted to be kicking off the 2020 health care conference this year with Ascendis. I'm joined up here by the company's President and CEO, Jan Mikkelsen. And just as a heads up, after he gives his presentation, which will hopefully touch on some of the updates of the company in press release last night, we're going to do a breakout session for more Q&A. It's right down the hall that way in the Yorkshire room. You can follow me. So I'll see you there. And I'll turn it over to Jan.
¸ - /- -
First of all, thanks, Jess, for inviting us to come here to San Francisco. And thank you for everyone to joining us today to hear about Ascendis Pharma.
As a reminder, I will making forward-looking statements, please refer to our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
